Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
17,819
archived clinical trials in
Brain Cancer

Collecting and Storing Blood Samples From Patients With Cancer
Banking DNA for Analysis of Genetic Polymorphisms in Patients With Cancer
Status: Archived
University of Medicine and Dentistry - Robert Wood Johnson University Hospital
1263
mi
from
New Brunswick, NJ
Collecting and Storing Blood Samples From Patients With Cancer
Banking DNA for Analysis of Genetic Polymorphisms in Patients With Cancer
Status: Archived
Updated: 1/1/1970
University of Medicine and Dentistry - Robert Wood Johnson University Hospital
1263
mi
from
New Brunswick, NJ
Reproducibility of 18F Uptake by Solid Tumors Using PET Imaging Following Intravenous Administration of (18F) Injection
A Test-retest Study to Assess Reproducibility of 18F Uptake by Solid Tumors Using PET Imaging Following Intravenous Administration of AH111585 (18F) Injection.
Status: Archived
101 Carnegie Center
1252
mi
from
Princeton, NJ
Reproducibility of 18F Uptake by Solid Tumors Using PET Imaging Following Intravenous Administration of (18F) Injection
A Test-retest Study to Assess Reproducibility of 18F Uptake by Solid Tumors Using PET Imaging Following Intravenous Administration of AH111585 (18F) Injection.
Status: Archived
Updated: 1/1/1970
101 Carnegie Center
1252
mi
from
Princeton, NJ
Pazopanib Hydrochloride in Treating Young Patients With Solid Tumors That Have Relapsed or Not Responded to Treatment
A Phase I Study of Pazopanib as a Single Agent for Children With Relapsed or Refractory Solid Tumors
Status: Archived
UAB Comprehensive Cancer Center
684
mi
from
Birmingham, AL
Pazopanib Hydrochloride in Treating Young Patients With Solid Tumors That Have Relapsed or Not Responded to Treatment
A Phase I Study of Pazopanib as a Single Agent for Children With Relapsed or Refractory Solid Tumors
Status: Archived
Updated: 1/1/1970
UAB Comprehensive Cancer Center
684
mi
from
Birmingham, AL
Pazopanib Hydrochloride in Treating Young Patients With Solid Tumors That Have Relapsed or Not Responded to Treatment
A Phase I Study of Pazopanib as a Single Agent for Children With Relapsed or Refractory Solid Tumors
Status: Archived
Children's Hospital
974
mi
from
Pittsburgh, PA
Pazopanib Hydrochloride in Treating Young Patients With Solid Tumors That Have Relapsed or Not Responded to Treatment
A Phase I Study of Pazopanib as a Single Agent for Children With Relapsed or Refractory Solid Tumors
Status: Archived
Updated: 1/1/1970
Children's Hospital
974
mi
from
Pittsburgh, PA
Pazopanib Hydrochloride in Treating Young Patients With Solid Tumors That Have Relapsed or Not Responded to Treatment
A Phase I Study of Pazopanib as a Single Agent for Children With Relapsed or Refractory Solid Tumors
Status: Archived
Children's Nutrition Research Center, Baylor College of Medicine
572
mi
from
Houston, TX
Pazopanib Hydrochloride in Treating Young Patients With Solid Tumors That Have Relapsed or Not Responded to Treatment
A Phase I Study of Pazopanib as a Single Agent for Children With Relapsed or Refractory Solid Tumors
Status: Archived
Updated: 1/1/1970
Children's Nutrition Research Center, Baylor College of Medicine
572
mi
from
Houston, TX
Pazopanib Hydrochloride in Treating Young Patients With Solid Tumors That Have Relapsed or Not Responded to Treatment
A Phase I Study of Pazopanib as a Single Agent for Children With Relapsed or Refractory Solid Tumors
Status: Archived
Children's Hospital - Boston
1441
mi
from
Boston, MA
Pazopanib Hydrochloride in Treating Young Patients With Solid Tumors That Have Relapsed or Not Responded to Treatment
A Phase I Study of Pazopanib as a Single Agent for Children With Relapsed or Refractory Solid Tumors
Status: Archived
Updated: 1/1/1970
Children's Hospital - Boston
1441
mi
from
Boston, MA
Pazopanib Hydrochloride in Treating Young Patients With Solid Tumors That Have Relapsed or Not Responded to Treatment
A Phase I Study of Pazopanib as a Single Agent for Children With Relapsed or Refractory Solid Tumors
Status: Archived
Indiana University Adult Psychiatry Clinic
643
mi
from
Indianapolis, IN
Pazopanib Hydrochloride in Treating Young Patients With Solid Tumors That Have Relapsed or Not Responded to Treatment
A Phase I Study of Pazopanib as a Single Agent for Children With Relapsed or Refractory Solid Tumors
Status: Archived
Updated: 1/1/1970
Indiana University Adult Psychiatry Clinic
643
mi
from
Indianapolis, IN
Pazopanib Hydrochloride in Treating Young Patients With Solid Tumors That Have Relapsed or Not Responded to Treatment
A Phase I Study of Pazopanib as a Single Agent for Children With Relapsed or Refractory Solid Tumors
Status: Archived
National Cancer Institute (NCI)
1123
mi
from
Bethesda, MD
Pazopanib Hydrochloride in Treating Young Patients With Solid Tumors That Have Relapsed or Not Responded to Treatment
A Phase I Study of Pazopanib as a Single Agent for Children With Relapsed or Refractory Solid Tumors
Status: Archived
Updated: 1/1/1970
National Cancer Institute (NCI)
1123
mi
from
Bethesda, MD
Pazopanib Hydrochloride in Treating Young Patients With Solid Tumors That Have Relapsed or Not Responded to Treatment
A Phase I Study of Pazopanib as a Single Agent for Children With Relapsed or Refractory Solid Tumors
Status: Archived
Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute
1441
mi
from
Boston, MA
Pazopanib Hydrochloride in Treating Young Patients With Solid Tumors That Have Relapsed or Not Responded to Treatment
A Phase I Study of Pazopanib as a Single Agent for Children With Relapsed or Refractory Solid Tumors
Status: Archived
Updated: 1/1/1970
Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute
1441
mi
from
Boston, MA
Pazopanib Hydrochloride in Treating Young Patients With Solid Tumors That Have Relapsed or Not Responded to Treatment
A Phase I Study of Pazopanib as a Single Agent for Children With Relapsed or Refractory Solid Tumors
Status: Archived
C.S Mott Children's Hospital
807
mi
from
Ann Arbor, MI
Pazopanib Hydrochloride in Treating Young Patients With Solid Tumors That Have Relapsed or Not Responded to Treatment
A Phase I Study of Pazopanib as a Single Agent for Children With Relapsed or Refractory Solid Tumors
Status: Archived
Updated: 1/1/1970
C.S Mott Children's Hospital
807
mi
from
Ann Arbor, MI
Pazopanib Hydrochloride in Treating Young Patients With Solid Tumors That Have Relapsed or Not Responded to Treatment
A Phase I Study of Pazopanib as a Single Agent for Children With Relapsed or Refractory Solid Tumors
Status: Archived
Masonic Cancer Center at University of Minnesota
552
mi
from
Minneapolis, MN
Pazopanib Hydrochloride in Treating Young Patients With Solid Tumors That Have Relapsed or Not Responded to Treatment
A Phase I Study of Pazopanib as a Single Agent for Children With Relapsed or Refractory Solid Tumors
Status: Archived
Updated: 1/1/1970
Masonic Cancer Center at University of Minnesota
552
mi
from
Minneapolis, MN
Pazopanib Hydrochloride in Treating Young Patients With Solid Tumors That Have Relapsed or Not Responded to Treatment
A Phase I Study of Pazopanib as a Single Agent for Children With Relapsed or Refractory Solid Tumors
Status: Archived
Siteman Cancer Center
414
mi
from
St. Louis, MO
Pazopanib Hydrochloride in Treating Young Patients With Solid Tumors That Have Relapsed or Not Responded to Treatment
A Phase I Study of Pazopanib as a Single Agent for Children With Relapsed or Refractory Solid Tumors
Status: Archived
Updated: 1/1/1970
Siteman Cancer Center
414
mi
from
St. Louis, MO
Pazopanib Hydrochloride in Treating Young Patients With Solid Tumors That Have Relapsed or Not Responded to Treatment
A Phase I Study of Pazopanib as a Single Agent for Children With Relapsed or Refractory Solid Tumors
Status: Archived
Columbia Presbyterian Med Ctr
1290
mi
from
New York, NY
Pazopanib Hydrochloride in Treating Young Patients With Solid Tumors That Have Relapsed or Not Responded to Treatment
A Phase I Study of Pazopanib as a Single Agent for Children With Relapsed or Refractory Solid Tumors
Status: Archived
Updated: 1/1/1970
Columbia Presbyterian Med Ctr
1290
mi
from
New York, NY
Pazopanib Hydrochloride in Treating Young Patients With Solid Tumors That Have Relapsed or Not Responded to Treatment
A Phase I Study of Pazopanib as a Single Agent for Children With Relapsed or Refractory Solid Tumors
Status: Archived
Cincinnati Children's Hospital Medical Center
726
mi
from
Cincinnati, OH
Pazopanib Hydrochloride in Treating Young Patients With Solid Tumors That Have Relapsed or Not Responded to Treatment
A Phase I Study of Pazopanib as a Single Agent for Children With Relapsed or Refractory Solid Tumors
Status: Archived
Updated: 1/1/1970
Cincinnati Children's Hospital Medical Center
726
mi
from
Cincinnati, OH
Pazopanib Hydrochloride in Treating Young Patients With Solid Tumors That Have Relapsed or Not Responded to Treatment
A Phase I Study of Pazopanib as a Single Agent for Children With Relapsed or Refractory Solid Tumors
Status: Archived
Knight Cancer Institute at Oregon Health and Science University
1384
mi
from
Portland, OR
Pazopanib Hydrochloride in Treating Young Patients With Solid Tumors That Have Relapsed or Not Responded to Treatment
A Phase I Study of Pazopanib as a Single Agent for Children With Relapsed or Refractory Solid Tumors
Status: Archived
Updated: 1/1/1970
Knight Cancer Institute at Oregon Health and Science University
1384
mi
from
Portland, OR
Pazopanib Hydrochloride in Treating Young Patients With Solid Tumors That Have Relapsed or Not Responded to Treatment
A Phase I Study of Pazopanib as a Single Agent for Children With Relapsed or Refractory Solid Tumors
Status: Archived
Children's Hospital at Downstate
1290
mi
from
Brooklyn, NY
Pazopanib Hydrochloride in Treating Young Patients With Solid Tumors That Have Relapsed or Not Responded to Treatment
A Phase I Study of Pazopanib as a Single Agent for Children With Relapsed or Refractory Solid Tumors
Status: Archived
Updated: 1/1/1970
Children's Hospital at Downstate
1290
mi
from
Brooklyn, NY
Pazopanib Hydrochloride in Treating Young Patients With Solid Tumors That Have Relapsed or Not Responded to Treatment
A Phase I Study of Pazopanib as a Single Agent for Children With Relapsed or Refractory Solid Tumors
Status: Archived
Children's Hospital of Pittsburgh - University of Pittsburgh Medical Center
974
mi
from
Pittsburgh, PA
Pazopanib Hydrochloride in Treating Young Patients With Solid Tumors That Have Relapsed or Not Responded to Treatment
A Phase I Study of Pazopanib as a Single Agent for Children With Relapsed or Refractory Solid Tumors
Status: Archived
Updated: 1/1/1970
Children's Hospital of Pittsburgh - University of Pittsburgh Medical Center
974
mi
from
Pittsburgh, PA
Pazopanib Hydrochloride in Treating Young Patients With Solid Tumors That Have Relapsed or Not Responded to Treatment
A Phase I Study of Pazopanib as a Single Agent for Children With Relapsed or Refractory Solid Tumors
Status: Archived
St. Jude Childrens Research Hosp, Memphis
468
mi
from
Memphis, TN
Pazopanib Hydrochloride in Treating Young Patients With Solid Tumors That Have Relapsed or Not Responded to Treatment
A Phase I Study of Pazopanib as a Single Agent for Children With Relapsed or Refractory Solid Tumors
Status: Archived
Updated: 1/1/1970
St. Jude Childrens Research Hosp, Memphis
468
mi
from
Memphis, TN
Pazopanib Hydrochloride in Treating Young Patients With Solid Tumors That Have Relapsed or Not Responded to Treatment
A Phase I Study of Pazopanib as a Single Agent for Children With Relapsed or Refractory Solid Tumors
Status: Archived
Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas
349
mi
from
Dallas, TX
Pazopanib Hydrochloride in Treating Young Patients With Solid Tumors That Have Relapsed or Not Responded to Treatment
A Phase I Study of Pazopanib as a Single Agent for Children With Relapsed or Refractory Solid Tumors
Status: Archived
Updated: 1/1/1970
Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas
349
mi
from
Dallas, TX
Pazopanib Hydrochloride in Treating Young Patients With Solid Tumors That Have Relapsed or Not Responded to Treatment
A Phase I Study of Pazopanib as a Single Agent for Children With Relapsed or Refractory Solid Tumors
Status: Archived
Baylor School of Medicine
572
mi
from
Houston, TX
Pazopanib Hydrochloride in Treating Young Patients With Solid Tumors That Have Relapsed or Not Responded to Treatment
A Phase I Study of Pazopanib as a Single Agent for Children With Relapsed or Refractory Solid Tumors
Status: Archived
Updated: 1/1/1970
Baylor School of Medicine
572
mi
from
Houston, TX
Pazopanib Hydrochloride in Treating Young Patients With Solid Tumors That Have Relapsed or Not Responded to Treatment
A Phase I Study of Pazopanib as a Single Agent for Children With Relapsed or Refractory Solid Tumors
Status: Archived
Children's Hospital and Regional Medical Center - Seattle
1409
mi
from
Seattle, WA
Pazopanib Hydrochloride in Treating Young Patients With Solid Tumors That Have Relapsed or Not Responded to Treatment
A Phase I Study of Pazopanib as a Single Agent for Children With Relapsed or Refractory Solid Tumors
Status: Archived
Updated: 1/1/1970
Children's Hospital and Regional Medical Center - Seattle
1409
mi
from
Seattle, WA
AZD2171 and Whole Brain Radiation Therapy (WBRT) in Patients With Brain Metastases
A Phase I Study of AZD2171 and WBRT in Patients With Brain Metastases
Status: Archived
Massachusetts General Hospital
1443
mi
from
Boston, MA
AZD2171 and Whole Brain Radiation Therapy (WBRT) in Patients With Brain Metastases
A Phase I Study of AZD2171 and WBRT in Patients With Brain Metastases
Status: Archived
Updated: 1/1/1970
Massachusetts General Hospital
1443
mi
from
Boston, MA
AZD2171 and Whole Brain Radiation Therapy (WBRT) in Patients With Brain Metastases
A Phase I Study of AZD2171 and WBRT in Patients With Brain Metastases
Status: Archived
Dana-Farber Cancer Institute
1444
mi
from
Boston, MA
AZD2171 and Whole Brain Radiation Therapy (WBRT) in Patients With Brain Metastases
A Phase I Study of AZD2171 and WBRT in Patients With Brain Metastases
Status: Archived
Updated: 1/1/1970
Dana-Farber Cancer Institute
1444
mi
from
Boston, MA
Suberoylanilide Hydroxamic Acid (SAHA), Bevacizumab, Daily Temozolomide for Recurrent Malignant Gliomas
Phase I/II Study of Bevacizumab Plus Daily Temozolomide and Vorinostat for Recurrent Malignant Glioma Patients
Status: Archived
Duke Univ Med Ctr
1052
mi
from
Durham, NC
Suberoylanilide Hydroxamic Acid (SAHA), Bevacizumab, Daily Temozolomide for Recurrent Malignant Gliomas
Phase I/II Study of Bevacizumab Plus Daily Temozolomide and Vorinostat for Recurrent Malignant Glioma Patients
Status: Archived
Updated: 1/1/1970
Duke Univ Med Ctr
1052
mi
from
Durham, NC
A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors
A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors
Status: Archived
Stanford university Hospital and Clinics
1329
mi
from
Stanford, CA
A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors
A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors
Status: Archived
Updated: 1/1/1970
Stanford university Hospital and Clinics
1329
mi
from
Stanford, CA
Trial of the Combination of Bevacizumab and Everolimus in Patients With Refractory, Progressive Intracranial Meningioma
A Phase II Trial of the Combination of Bevacizumab and Everolimus in Patients With Refractory, Progressive Intracranial Meningioma
Status: Archived
Cancer Institute of Florida, PA - Orlando
1140
mi
from
Orlando, FL
Trial of the Combination of Bevacizumab and Everolimus in Patients With Refractory, Progressive Intracranial Meningioma
A Phase II Trial of the Combination of Bevacizumab and Everolimus in Patients With Refractory, Progressive Intracranial Meningioma
Status: Archived
Updated: 1/1/1970
Cancer Institute of Florida, PA - Orlando
1140
mi
from
Orlando, FL
Trial of the Combination of Bevacizumab and Everolimus in Patients With Refractory, Progressive Intracranial Meningioma
A Phase II Trial of the Combination of Bevacizumab and Everolimus in Patients With Refractory, Progressive Intracranial Meningioma
Status: Archived
Northeast Georgia Heart Center, PC
816
mi
from
Gainesville, FL
Trial of the Combination of Bevacizumab and Everolimus in Patients With Refractory, Progressive Intracranial Meningioma
A Phase II Trial of the Combination of Bevacizumab and Everolimus in Patients With Refractory, Progressive Intracranial Meningioma
Status: Archived
Updated: 1/1/1970
Northeast Georgia Heart Center, PC
816
mi
from
Gainesville, FL
Trial of the Combination of Bevacizumab and Everolimus in Patients With Refractory, Progressive Intracranial Meningioma
A Phase II Trial of the Combination of Bevacizumab and Everolimus in Patients With Refractory, Progressive Intracranial Meningioma
Status: Archived
Nebraska Methodist Hospital
260
mi
from
Omaha, NE
Trial of the Combination of Bevacizumab and Everolimus in Patients With Refractory, Progressive Intracranial Meningioma
A Phase II Trial of the Combination of Bevacizumab and Everolimus in Patients With Refractory, Progressive Intracranial Meningioma
Status: Archived
Updated: 1/1/1970
Nebraska Methodist Hospital
260
mi
from
Omaha, NE
Trial of the Combination of Bevacizumab and Everolimus in Patients With Refractory, Progressive Intracranial Meningioma
A Phase II Trial of the Combination of Bevacizumab and Everolimus in Patients With Refractory, Progressive Intracranial Meningioma
Status: Archived
University of Pittsburgh Medical Center
974
mi
from
Pittsburgh, PA
Trial of the Combination of Bevacizumab and Everolimus in Patients With Refractory, Progressive Intracranial Meningioma
A Phase II Trial of the Combination of Bevacizumab and Everolimus in Patients With Refractory, Progressive Intracranial Meningioma
Status: Archived
Updated: 1/1/1970
University of Pittsburgh Medical Center
974
mi
from
Pittsburgh, PA
Trial of the Combination of Bevacizumab and Everolimus in Patients With Refractory, Progressive Intracranial Meningioma
A Phase II Trial of the Combination of Bevacizumab and Everolimus in Patients With Refractory, Progressive Intracranial Meningioma
Status: Archived
Tennessee Oncology, PLLC
558
mi
from
Nashville, TN
Trial of the Combination of Bevacizumab and Everolimus in Patients With Refractory, Progressive Intracranial Meningioma
A Phase II Trial of the Combination of Bevacizumab and Everolimus in Patients With Refractory, Progressive Intracranial Meningioma
Status: Archived
Updated: 1/1/1970
Tennessee Oncology, PLLC
558
mi
from
Nashville, TN
The Effect of Monoclonal Vascular Endothelial Growth Factor (VEGF) Antibody (Bevacizumab) on Pituitary Function
The Effect of Monoclonal Vascular Endothelial Growth Factor (VEGF) Antibody (Bevacizumab) on Pituitary Function
Status: Archived
Cedars-Sinai Medical Center
1168
mi
from
Los Angeles, CA
The Effect of Monoclonal Vascular Endothelial Growth Factor (VEGF) Antibody (Bevacizumab) on Pituitary Function
The Effect of Monoclonal Vascular Endothelial Growth Factor (VEGF) Antibody (Bevacizumab) on Pituitary Function
Status: Archived
Updated: 1/1/1970
Cedars-Sinai Medical Center
1168
mi
from
Los Angeles, CA
Avastin/Temozolomide/Irinotecan for Unresectable/Multifocal Glioblastoma Multiforme Multiforme
Avastin in Combination With Temozolomide and Irinotecan for Unresectable or Multifocal Glioblastoma Multiformes and Gliosarcomas
Status: Archived
The Preston Robert Tisch Brain Tumor Center
1052
mi
from
Durham, NC
Avastin/Temozolomide/Irinotecan for Unresectable/Multifocal Glioblastoma Multiforme Multiforme
Avastin in Combination With Temozolomide and Irinotecan for Unresectable or Multifocal Glioblastoma Multiformes and Gliosarcomas
Status: Archived
Updated: 1/1/1970
The Preston Robert Tisch Brain Tumor Center
1052
mi
from
Durham, NC
Vascular Endothelial Growth Factor (VEGF) Levels in Brain Tumor Patients
Is VEGF a Useful Serum Biomarker for Patients Diagnosed With Meningioma or Glioma?
Status: Archived
Marquette General Health System
807
mi
from
Marquette, MI
Vascular Endothelial Growth Factor (VEGF) Levels in Brain Tumor Patients
Is VEGF a Useful Serum Biomarker for Patients Diagnosed With Meningioma or Glioma?
Status: Archived
Updated: 1/1/1970
Marquette General Health System
807
mi
from
Marquette, MI
Presurgery Bortezomib for Recurrent Malignant Gliomas Followed by Postop Bortezomib & Temozolomide
A Phase II Trial Evaluating the Effects of Bortezomib in Patients With Recurrent Malignant Gliomas Treated Prior to Surgery and Then Bortezomib and Temozolomide Post-operatively
Status: Archived
Northwestern University
611
mi
from
Chicago, IL
Presurgery Bortezomib for Recurrent Malignant Gliomas Followed by Postop Bortezomib & Temozolomide
A Phase II Trial Evaluating the Effects of Bortezomib in Patients With Recurrent Malignant Gliomas Treated Prior to Surgery and Then Bortezomib and Temozolomide Post-operatively
Status: Archived
Updated: 1/1/1970
Northwestern University
611
mi
from
Chicago, IL
Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma
A Phase I Study of Vorinostat and Bortezomib in Children With Refractory or Recurrent Solid Tumors, Including CNS Tumors and Lymphomas
Status: Archived
UAB Comprehensive Cancer Center
684
mi
from
Birmingham, AL
Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma
A Phase I Study of Vorinostat and Bortezomib in Children With Refractory or Recurrent Solid Tumors, Including CNS Tumors and Lymphomas
Status: Archived
Updated: 1/1/1970
UAB Comprehensive Cancer Center
684
mi
from
Birmingham, AL
Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma
A Phase I Study of Vorinostat and Bortezomib in Children With Refractory or Recurrent Solid Tumors, Including CNS Tumors and Lymphomas
Status: Archived
Children's Hospital
974
mi
from
Pittsburgh, PA
Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma
A Phase I Study of Vorinostat and Bortezomib in Children With Refractory or Recurrent Solid Tumors, Including CNS Tumors and Lymphomas
Status: Archived
Updated: 1/1/1970
Children's Hospital
974
mi
from
Pittsburgh, PA
Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma
A Phase I Study of Vorinostat and Bortezomib in Children With Refractory or Recurrent Solid Tumors, Including CNS Tumors and Lymphomas
Status: Archived
Children's Nutrition Research Center, Baylor College of Medicine
572
mi
from
Houston, TX
Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma
A Phase I Study of Vorinostat and Bortezomib in Children With Refractory or Recurrent Solid Tumors, Including CNS Tumors and Lymphomas
Status: Archived
Updated: 1/1/1970
Children's Nutrition Research Center, Baylor College of Medicine
572
mi
from
Houston, TX
Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma
A Phase I Study of Vorinostat and Bortezomib in Children With Refractory or Recurrent Solid Tumors, Including CNS Tumors and Lymphomas
Status: Archived
Children's Hospital - Boston
1441
mi
from
Boston, MA
Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma
A Phase I Study of Vorinostat and Bortezomib in Children With Refractory or Recurrent Solid Tumors, Including CNS Tumors and Lymphomas
Status: Archived
Updated: 1/1/1970
Children's Hospital - Boston
1441
mi
from
Boston, MA
Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma
A Phase I Study of Vorinostat and Bortezomib in Children With Refractory or Recurrent Solid Tumors, Including CNS Tumors and Lymphomas
Status: Archived
Indiana University Adult Psychiatry Clinic
643
mi
from
Indianapolis, IN
Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma
A Phase I Study of Vorinostat and Bortezomib in Children With Refractory or Recurrent Solid Tumors, Including CNS Tumors and Lymphomas
Status: Archived
Updated: 1/1/1970
Indiana University Adult Psychiatry Clinic
643
mi
from
Indianapolis, IN
Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma
A Phase I Study of Vorinostat and Bortezomib in Children With Refractory or Recurrent Solid Tumors, Including CNS Tumors and Lymphomas
Status: Archived
National Cancer Institute (NCI)
1123
mi
from
Bethesda, MD
Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma
A Phase I Study of Vorinostat and Bortezomib in Children With Refractory or Recurrent Solid Tumors, Including CNS Tumors and Lymphomas
Status: Archived
Updated: 1/1/1970
National Cancer Institute (NCI)
1123
mi
from
Bethesda, MD
Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma
A Phase I Study of Vorinostat and Bortezomib in Children With Refractory or Recurrent Solid Tumors, Including CNS Tumors and Lymphomas
Status: Archived
Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute
1441
mi
from
Boston, MA
Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma
A Phase I Study of Vorinostat and Bortezomib in Children With Refractory or Recurrent Solid Tumors, Including CNS Tumors and Lymphomas
Status: Archived
Updated: 1/1/1970
Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute
1441
mi
from
Boston, MA
Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma
A Phase I Study of Vorinostat and Bortezomib in Children With Refractory or Recurrent Solid Tumors, Including CNS Tumors and Lymphomas
Status: Archived
C.S Mott Children's Hospital
807
mi
from
Ann Arbor, MI
Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma
A Phase I Study of Vorinostat and Bortezomib in Children With Refractory or Recurrent Solid Tumors, Including CNS Tumors and Lymphomas
Status: Archived
Updated: 1/1/1970
C.S Mott Children's Hospital
807
mi
from
Ann Arbor, MI
Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma
A Phase I Study of Vorinostat and Bortezomib in Children With Refractory or Recurrent Solid Tumors, Including CNS Tumors and Lymphomas
Status: Archived
Masonic Cancer Center at University of Minnesota
552
mi
from
Minneapolis, MN
Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma
A Phase I Study of Vorinostat and Bortezomib in Children With Refractory or Recurrent Solid Tumors, Including CNS Tumors and Lymphomas
Status: Archived
Updated: 1/1/1970
Masonic Cancer Center at University of Minnesota
552
mi
from
Minneapolis, MN
Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma
A Phase I Study of Vorinostat and Bortezomib in Children With Refractory or Recurrent Solid Tumors, Including CNS Tumors and Lymphomas
Status: Archived
Siteman Cancer Center
414
mi
from
St. Louis, MO
Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma
A Phase I Study of Vorinostat and Bortezomib in Children With Refractory or Recurrent Solid Tumors, Including CNS Tumors and Lymphomas
Status: Archived
Updated: 1/1/1970
Siteman Cancer Center
414
mi
from
St. Louis, MO
Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma
A Phase I Study of Vorinostat and Bortezomib in Children With Refractory or Recurrent Solid Tumors, Including CNS Tumors and Lymphomas
Status: Archived
Columbia Presbyterian Med Ctr
1290
mi
from
New York, NY
Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma
A Phase I Study of Vorinostat and Bortezomib in Children With Refractory or Recurrent Solid Tumors, Including CNS Tumors and Lymphomas
Status: Archived
Updated: 1/1/1970
Columbia Presbyterian Med Ctr
1290
mi
from
New York, NY
Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma
A Phase I Study of Vorinostat and Bortezomib in Children With Refractory or Recurrent Solid Tumors, Including CNS Tumors and Lymphomas
Status: Archived
Cincinnati Children's Hospital Medical Center
726
mi
from
Cincinnati, OH
Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma
A Phase I Study of Vorinostat and Bortezomib in Children With Refractory or Recurrent Solid Tumors, Including CNS Tumors and Lymphomas
Status: Archived
Updated: 1/1/1970
Cincinnati Children's Hospital Medical Center
726
mi
from
Cincinnati, OH
Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma
A Phase I Study of Vorinostat and Bortezomib in Children With Refractory or Recurrent Solid Tumors, Including CNS Tumors and Lymphomas
Status: Archived
Knight Cancer Institute at Oregon Health and Science University
1384
mi
from
Portland, OR
Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma
A Phase I Study of Vorinostat and Bortezomib in Children With Refractory or Recurrent Solid Tumors, Including CNS Tumors and Lymphomas
Status: Archived
Updated: 1/1/1970
Knight Cancer Institute at Oregon Health and Science University
1384
mi
from
Portland, OR
Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma
A Phase I Study of Vorinostat and Bortezomib in Children With Refractory or Recurrent Solid Tumors, Including CNS Tumors and Lymphomas
Status: Archived
Children's Hospital at Downstate
1290
mi
from
Brooklyn, NY
Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma
A Phase I Study of Vorinostat and Bortezomib in Children With Refractory or Recurrent Solid Tumors, Including CNS Tumors and Lymphomas
Status: Archived
Updated: 1/1/1970
Children's Hospital at Downstate
1290
mi
from
Brooklyn, NY
Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma
A Phase I Study of Vorinostat and Bortezomib in Children With Refractory or Recurrent Solid Tumors, Including CNS Tumors and Lymphomas
Status: Archived
Children's Hospital of Pittsburgh - University of Pittsburgh Medical Center
974
mi
from
Pittsburgh, PA
Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma
A Phase I Study of Vorinostat and Bortezomib in Children With Refractory or Recurrent Solid Tumors, Including CNS Tumors and Lymphomas
Status: Archived
Updated: 1/1/1970
Children's Hospital of Pittsburgh - University of Pittsburgh Medical Center
974
mi
from
Pittsburgh, PA
Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma
A Phase I Study of Vorinostat and Bortezomib in Children With Refractory or Recurrent Solid Tumors, Including CNS Tumors and Lymphomas
Status: Archived
St. Jude Childrens Research Hosp, Memphis
468
mi
from
Memphis, TN
Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma
A Phase I Study of Vorinostat and Bortezomib in Children With Refractory or Recurrent Solid Tumors, Including CNS Tumors and Lymphomas
Status: Archived
Updated: 1/1/1970
St. Jude Childrens Research Hosp, Memphis
468
mi
from
Memphis, TN